MicroRNA Let-7b: A Non-coding RNA Molecule with Potential as A Drug Target Or Biomarker

Target Name: CERNA2

NCBI ID: G642934

CERNA2

Other Name(s): competing endogenous lncRNA 2 for microRNA let-7b | HOST2 | lncRNA-HOST2 | Competing endogenous lncRNA 2 for microRNA let-7b

MicroRNA Let-7b: A Non-coding RNA Molecule with Potential as A Drug Target Or Biomarker

MicroRNA let-7b is a non-coding RNA molecule that plays a critical role in regulating gene expression in various organisms, including humans. Mutations in the let-7b gene have been linked to a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. The study of let-7b and its associated microRNAs is an active area of research, with a focus on understanding its function and potential as a drug target or biomarker.

One of the defining features of microRNAs is their ability to interact with their target RNAs to regulate their stability and translation efficiency. This interaction between microRNAs and their target RNAs is typically mediated by the protein splicing machinery, which is responsible for the production of RNA from DNA templates. One of the key challenges in the study of microRNAs is to understand how they interact with their target RNAs and how this interaction contributes to their regulation.

One of the most well-studied microRNAs is let-7b, which is a non-coding RNA molecule that is expressed in various tissues and organs in the body.let-7b has been shown to play a critical role in regulating gene expression in various organisms, including humans. Studies have shown that let-7b is involved in a number of cellular processes, including cell growth, apoptosis, and inflammation.

One of the defining features of let-7b is its ability to interact with its target RNAs to regulate their stability and translation efficiency. This interaction between let-7b and its target RNAs is typically mediated by the protein splicing machinery, which is responsible for the production of RNA from DNA templates. One of the key challenges in the study of let-7b and its interactions with other microRNAs is to understand how these interactions contribute to its regulation.

One of the key goals of research into let-7b is to understand its function as a drug target or biomarker. Studies have shown that let-7b is involved in a number of cellular processes that are potentially relevant to a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, the study of let-7b and its interactions with other microRNAs is an important area of research that has the potential to shed light on the mechanisms underlying these diseases and to identify new therapeutic targets.

In addition to its potential as a drug target or biomarker, let-7b is also of interest as a potential therapeutic agent for a variety of diseases. Studies have shown that let-7b can be expressed and administered to animals in a variety of formats, including plasmid-based delivery, RNA-based delivery, and nanoparticle-based delivery. These delivery formats can potentially allow for the safe and effective treatment of a wide range of diseases.

Overall, the study of let-7b and its associated microRNAs is an important area of research that has the potential to shed light on the mechanisms underlying various diseases and to identify new therapeutic targets. The regulation of gene expression by microRNAs is a complex process that is still being fully understood, and the study of let-7b and its interactions with other microRNAs is an important step in this process. Further research is needed to fully understand the role of let-7b in various cellular processes and to explore its potential as a drug target or biomarker.

Protein Name: Competing Endogenous LncRNA 2 For MicroRNA Let-7b

The "CERNA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CERNA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets